About this Journal Submit a Manuscript Table of Contents
Journal of Biomedicine and Biotechnology
Volume 2010 (2010), Article ID 354068, 19 pages
http://dx.doi.org/10.1155/2010/354068
Review Article

Bridging Innate and Adaptive Antitumor Immunity Targeting Glycans

1Department of Pathology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, 4301 West Markham St., Slot no.824, Little Rock, AR 72205, USA
2Bioinformatics Centre, Institute of Microbial Technology, Sector 39A, Chandigarh 160036, India

Received 26 January 2010; Accepted 22 April 2010

Academic Editor: Hanchun Yang

Copyright © 2010 Anastas Pashov et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. Chaudhuri, R. Suriano, A. Mittelman, and R. K. Tiwari, “Targeting the immune system in cancer,” Current Pharmaceutical Biotechnology, vol. 10, no. 2, pp. 166–184, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. N. Bhardwaj, “Harnessing the immune system to treat cancer,” Journal of Clinical Investigation, vol. 117, no. 5, pp. 1130–1136, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. J. C. Sun and L. L. Lanier, “Natural killer cells remember: an evolutionary bridge between innate and adaptive immunity?” European Journal of Immunology, vol. 39, no. 8, pp. 2059–2064, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. D. H. Raulet, “Interplay of natural killer cells and their receptors with the adaptive immune response,” Nature Immunology, vol. 5, no. 10, pp. 996–1002, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. J. D. Bui and R. D. Schreiber, “Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes?” Current Opinion in Immunology, vol. 19, no. 2, pp. 203–208, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. L. Zitvogel, A. Tesniere, and G. Kroemer, “Cancer despite immunosurveillance: immunoselection and immunosubversion,” Nature Reviews Immunology, vol. 6, no. 10, pp. 715–727, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. T. Boon and N. van Baren, “Immunosurveillance against cancer and immunotherapy—synergy or antagonism?” The New England Journal of Medicine, vol. 348, no. 3, pp. 252–254, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. A. F. Ochsenbein, P. Klenerman, U. Karrer, B. Ludewig, M. Pericin, H. Hengartner, and R. M. Zinkernagel, “Immune surveillance against a solid tumor fails because of immunological ignorance,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 5, pp. 2233–2238, 1999. View at Publisher · View at Google Scholar · View at Scopus
  9. H. P. Vollmers and S. Brändlein, “Natural antibodies and cancer,” New Biotechnology, vol. 25, no. 5, pp. 294–298, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. E. Toubi and Y. Shoenfeld, “Protective autoimmunity in cancer (review),” Oncology Reports, vol. 17, no. 1, pp. 245–251, 2007. View at Scopus
  11. M. Dougan and G. Dranoff, “Immune therapy for cancer,” Annual Review of Immunology, vol. 27, pp. 83–117, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. M. I. Nishimura, J. J. Roszkowski, T. V. Moore, N. Brasic, M. D. McKee, and T. M. Clay, “Antigen recognition and T-cell biology,” Cancer Treatment and Research, vol. 123, pp. 37–59, 2005. View at Scopus
  13. T. Boon, P. G. Coulie, B. J. van den Eynde, and P. van der Bruggen, “Human T cell responses against melanoma,” Annual Review of Immunology, vol. 24, pp. 175–208, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. M. L. Disis and K. H. Park, “Immunomodulation of breast cancer via tumor antigen specific Th1,” Cancer Research and Treatment, vol. 41, no. 3, pp. 117–121, 2009. View at Publisher · View at Google Scholar · View at PubMed
  15. G. Dranoff, “Targets of protective tumor immunity,” Annals of the New York Academy of Sciences, vol. 1174, pp. 74–80, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. A. Gray, A. B. Raff, M. Chiriva-Internati, S.-Y. Chen, and W. M. Kast, “A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting,” Immunological Reviews, vol. 222, no. 1, pp. 316–327, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. M. G. Carmichael, L. C. Benavides, J. P. Holmes, J. D. Gates, E. A. Mittendorf, S. Ponniah, and G. E. Peoples, “Results of the first phase 1 clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patients: United States Military Cancer Institute Clinical Trials Group Study I-04,” Cancer, vol. 116, no. 2, pp. 292–301, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. L. G. Salazar and M. L. Disis, “Cancer vaccines: the role of tumor burden in tipping the scale toward vaccine efficacy,” Journal of Clinical Oncology, vol. 23, no. 30, pp. 7397–7398, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. A. E. Seif, D. M. Barrett, M. Milone, V. I. Brown, S. A. Grupp, and G. S. D. Reid, “Long-term protection from syngeneic acute lymphoblastic leukemia by CpG ODN-mediated stimulation of innate and adaptive immune responses,” Blood, vol. 114, no. 12, pp. 2459–2466, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. M. R. Buckwalter and P. K. Srivastava, ““It is the antigen(s), stupid” and other lessons from over a decade of vaccitherapy of human cancer,” Seminars in Immunology, vol. 20, no. 5, pp. 296–300, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. M. Burnet, “Cancer; a biological approach. I. The processes of control,” British Medical Journal, vol. 1, no. 5022, pp. 779–786, 1957.
  22. P. Matzinger, “The danger model: a renewed sense of self,” Science, vol. 296, no. 5566, pp. 301–305, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. S. E. Martin and W. J. Martin, “Anti tumor antibodies in normal mouse sera,” International Journal of Cancer, vol. 15, no. 4, pp. 658–664, 1975. View at Scopus
  24. T. Takahashi, T. D. Johnson, Y. Nishinaka, D. L. Morton, and R. F. Irie, “IgM anti-ganglioside antibodies induced by melanoma cell vaccine correlate with survival of melanoma patients,” Journal of Investigative Dermatology, vol. 112, no. 2, pp. 205–209, 1999. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. F. Dair'Olio, “Protein glycosylation in cancer biology: an overview,” Journal of Clinical Pathology, vol. 49, no. 3, pp. M126–M135, 1996. View at Scopus
  26. U. Galili, “The α-gal epitope and the anti-Gal antibody in xenotransplantation and in cancer immunotherapy,” Immunology and Cell Biology, vol. 83, no. 6, pp. 674–686, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. P. Luo, G. Canziani, G. Cunto-Amesty, and T. Kieber-Emmons, “A molecular basis for functional peptide mimicry of a carbohydrate antigen,” Journal of Biological Chemistry, vol. 275, no. 21, pp. 16146–16154, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. G. Cunto-Amesty, T. K. Dam, P. Luo, B. Monzavi-Karbassi, C. F. Brewer, T. C. Van Cott, and T. Kieber-Emmons, “Directing the immune response to carbohydrate antigens,” Journal of Biological Chemistry, vol. 276, no. 32, pp. 30490–30498, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. B. Monzavi-Karbassi, G. Cunto-Amesty, P. Luo, and T. Kieber-Emmons, “Peptide mimotopes as surrogate antigens of carbohydrates in vaccine discovery,” Trends in Biotechnology, vol. 20, no. 5, pp. 207–214, 2002. View at Publisher · View at Google Scholar · View at Scopus
  30. V. Apostolopoulos, M. S. Sandrin, and I. F. C. McKenzie, “Carbohydrate/peptide mimics: effect on MUC1 cancer immunotherapy,” Journal of Molecular Medicine, vol. 77, no. 5, pp. 427–436, 1999. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Pashov, B. Monzavi-Karbassi, M. Chow, M. Cannon, and T. Kieber-Emmons, “Immune surveillance as a rationale for immunotherapy?” Human Vaccines, vol. 3, no. 5, pp. 224–228, 2007. View at Scopus
  32. L. Vujanovic and L. H. Butterfield, “Melanoma cancer vaccines and anti-tumor T cell responses,” Journal of Cellular Biochemistry, vol. 102, no. 2, pp. 301–310, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  33. S. J. van Vliet, J. J. García-Vallejo, and Y. Van Kooyk, “Dendritic cells and C-type lectin receptors: coupling innate to adaptive immune responses,” Immunology and Cell Biology, vol. 86, no. 7, pp. 580–587, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  34. H. P. Vollmers and S. Brändlein, “Tumors: too sweet to remember?” Molecular Cancer, vol. 6, article 78, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  35. E. I. Buzás, B. György, M. Pásztói, I. Jelinek, A. Falus, and H.-J. Gabius, “Carbohydrate recognition systems in autoimmunity,” Autoimmunity, vol. 39, no. 8, pp. 691–704, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  36. U. Galili, “Immune response, accomodation, and tolerance to transplantation carbohydrate antigens,” Transplantation, vol. 78, no. 8, pp. 1093–1098, 2004. View at Publisher · View at Google Scholar · View at Scopus
  37. A. Weintraub, “Immunology of bacterial polysaccharide antigens,” Carbohydrate Research, vol. 338, no. 23, pp. 2539–2547, 2003. View at Publisher · View at Google Scholar · View at Scopus
  38. B. A. 'T Hart and Y. van Kooyk, “Yin-Yang regulation of autoimmunity by DCs,” Trends in Immunology, vol. 25, no. 7, pp. 353–359, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  39. M. H. Ravindranath, S. Muthugounder, M. R. Hannah, and D. L. Morton, “Significance of endogenous augmentation of antiganglioside IgM in cancer patients: potential tool for early detection and management of cancer therapy,” Annals of the New York Academy of Sciences, vol. 1107, pp. 212–222, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  40. B. A. Cobb and D. L. Kasper, “Coming of age: carbohydrates and immunity,” European Journal of Immunology, vol. 35, no. 2, pp. 352–356, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  41. H. Wang and S. H. Clarke, “Regulation of B-cell development by antibody specificity,” Current Opinion in Immunology, vol. 16, no. 2, pp. 246–250, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  42. J. B. Carey, C. S. Moffatt-Blue, L. C. Watson, A. L. Gavin, and A. J. Feeney, “Repertoire-based selection into the marginal zone compartment during B cell development,” Journal of Experimental Medicine, vol. 205, no. 9, pp. 2043–2052, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  43. X.-J. Zhao and N.-K. V. Cheung, “GD2 oligosaccharide: target for cytotoxic T lymphocytes,” Journal of Experimental Medicine, vol. 182, no. 1, pp. 67–74, 1995. View at Publisher · View at Google Scholar · View at Scopus
  44. M. V. Dhodapkar, “Harnessing human CD1d restricted T cells for tumor immunity: progress and challenges,” Frontiers in Bioscience, vol. 14, pp. 796–807, 2009. View at Scopus
  45. B. A. Cobb, Q. Wang, A. O. Tzianabos, and D. L. Kasper, “Polysaccharide processing and presentation by the MHCII pathway,” Cell, vol. 117, no. 5, pp. 677–687, 2004. View at Publisher · View at Google Scholar · View at Scopus
  46. A. M. Vlad, S. Muller, M. Cudic, H. Paulsen, L. Otvos Jr., F.-G. Hanisch, and O. J. Finn, “Complex carbohydrates are not removed during processing of glycoproteins by dendritic cells: processing of tumor antigen MUC1 glycopeptides for presentation to major histocompatibility complex class II-restricted T cells,” Journal of Experimental Medicine, vol. 196, no. 11, pp. 1435–1446, 2002. View at Publisher · View at Google Scholar · View at Scopus
  47. S. V. Evans, B. W. Sigurskjold, and B. W. Sigurskjold, “Evidence for the extended helical nature of polysaccharide epitopes. The 2.8 Å resolution structure and thermodynamics of ligand binding of an antigen binding fragment specific for α-(2→8)-polysialic acid,” Biochemistry, vol. 34, no. 20, pp. 6737–6744, 1995. View at Publisher · View at Google Scholar · View at Scopus
  48. C. Forestier, E. Moreno, S. Méresse, A. Phalipon, D. Olive, P. Sansonetti, and J.-P. Gorvel, “Interaction of Brucella abortus lipopolysaccharide with major histocompatibility complex class II molecules in B lymphocytes,” Infection and Immunity, vol. 67, no. 8, pp. 4048–4054, 1999. View at Scopus
  49. A. O. Tzianabos, R. W. Finberg, Y. Wang, M. Chan, A. B. Onderdonk, H. J. Jennings, and D. L. Kasper, “T cells activated by zwitterionic molecules prevent abscesses induced by pathogenic bacteria,” Journal of Biological Chemistry, vol. 275, no. 10, pp. 6733–6740, 2000. View at Publisher · View at Google Scholar · View at Scopus
  50. Y. van Kooyk, A. Engering, A. N. Lekkerkerker, I. S. Ludwig, and T. B. H. Geijtenbeek, “Pathogens use carbohydrates to escape immunity induced by dendritic cells,” Current Opinion in Immunology, vol. 16, no. 4, pp. 488–493, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  51. U. Galili, E. A. Rachmilewitz, A. Peleg, and I. Flechner, “A unique natural human IgG antibody with anti-α-galactosyl specificity,” Journal of Experimental Medicine, vol. 160, no. 5, pp. 1519–1531, 1984. View at Scopus
  52. U. Galili, R. E. Mandrell, R. M. Hamadeh, S. B. Shohet, and J. M. Griffiss, “Interaction between human natural anti-α-galactosyl immunoglobulin G and bacteria of the human flora,” Infection and Immunity, vol. 56, no. 7, pp. 1730–1737, 1988. View at Scopus
  53. I. M. MCmorrow, C. A. Comrack, D. H. Sachs, and H. DerSimonian, “Heterogeneity of human anti-pig natural antibodies cross-reactive with the Gal(α1,3)Galactose epitope,” Transplantation, vol. 64, no. 3, pp. 501–510, 1997. View at Publisher · View at Google Scholar · View at Scopus
  54. N. Barreau, G. Blancho, and G. Blancho, “Natural anti-Gal antibodies constitute 0.2% of intravenous immunoglobulin and are equally retained on a synthetic disaccharide column or on an immobilized natural glycoprotein,” Transplantation Proceedings, vol. 32, no. 5, pp. 882–883, 2000. View at Publisher · View at Google Scholar · View at Scopus
  55. M. Sæthre, U. Ø. Sølvik, and U. Ø. Sølvik, “Human serum-induced porcine endothelial cell E-selectin expression is associated with IgG3 and IgM anti-Gal antibodies,” Xenotransplantation, vol. 9, no. 5, pp. 350–358, 2002. View at Publisher · View at Google Scholar · View at Scopus
  56. J.-P. Dehoux, B. de la Parra, D. Latinne, H. Bazin, and P. Gianello, “Characterization of baboon anti-porcine IgG antibodies during acute vascular rejection of porcine kidney xenograft,” Xenotransplantation, vol. 9, no. 5, pp. 338–349, 2002. View at Publisher · View at Google Scholar · View at Scopus
  57. W. D. Jin, T. Zhou, and T. Zhou, “Hyperacute rejection by anti-Gal IgG1, IgG2a, and IgG2b is dependent on complement and Fc-γ receptors,” Journal of Immunology, vol. 180, no. 1, pp. 261–268, 2008. View at Scopus
  58. U. Galili and D. C. LaTemple, “Natural anti-Gal antibody as a universal augmenter of autologous tumor vaccine immunogenicity,” Immunology Today, vol. 18, no. 6, pp. 281–285, 1997. View at Scopus
  59. U. Galili, “Interaction of the natural anti-Gal antibody with α-galactosyl epitopes: a major obstacle for xenotransplantation in humans,” Immunology Today, vol. 14, no. 10, pp. 480–482, 1993. View at Publisher · View at Google Scholar · View at Scopus
  60. Y. Xu, A. Sette, J. Sidney, S. J. Gendler, and A. Franco, “Tumor-associated carbohydrate antigens: a possible avenue for cancer prevention,” Immunology and Cell Biology, vol. 83, no. 4, pp. 440–448, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  61. M. F. Wolf, U. Koerner, B. Klumpp, and K. Schumacher, “Characterization of Thomsen-Friedenreich antibody subpopulations from normal human serum,” Tumor Biology, vol. 8, no. 5, pp. 264–272, 1987. View at Scopus
  62. M. Zanetti, G. Lenert, and G. F. Springer, “Idiotypes of pre-existing human anti-carcinoma anti-T and anti-Tn antibodies,” International Immunology, vol. 5, no. 2, pp. 113–119, 1993. View at Scopus
  63. S. Hirohashi, H. Clausen, T. Yamada, Y. Shimosato, and S. Hakomori, “Blood group A cross-reacting epitope defined by monoclonal antibodies NCC-LU-35 and -81 expressed in cancer of blood group O or B individuals: its identification as Tn antigen,” Proceedings of the National Academy of Sciences of the United States of America, vol. 82, no. 20, pp. 7039–7043, 1985. View at Scopus
  64. U. Galili, J. Buehler, S. B. Shohet, and B. A. Macher, “The human natural anti-Gal IgG. III. The subtlety of immune tolerance in man as demonstrated by crossreactivity between natural anti-Gal and anti-B antibodies,” Journal of Experimental Medicine, vol. 165, no. 3, pp. 693–704, 1987. View at Scopus
  65. E. P. Smorodin, O. A. Kurtenkov, B. L. Sergeyev, K. E. Kodar, V. I. Chuzmarov, and V. P. Afanasyev, “Postoperative change of anti-Thomsen-Friedenreich and Tn IgG level: the follow-up study of gastrointestinal cancer patients,” World Journal of Gastroenterology, vol. 14, no. 27, pp. 4352–4358, 2008. View at Publisher · View at Google Scholar · View at Scopus
  66. O. Kurtenkov, K. Klaamas, S. Mensdorff-Pouilly, L. Miljukhina, L. Shljapnikova, and V. Chužmarov, “Humoral immune response to MUC1 and to the Thomsen-Friedenreich (TF) glycotope in patients with gastric cancer: relation to survival,” Acta Oncologica, vol. 46, no. 3, pp. 316–323, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  67. G. F. Springer, “Immunoreactive T and Tn epitopes in cancer diagnosis, prognosis, and immunotherapy,” Journal of Molecular Medicine, vol. 75, no. 8, pp. 594–602, 1997. View at Publisher · View at Google Scholar · View at Scopus
  68. F. R. Carbone and P. A. Gleeson, “Carbohydrates and antigen recognition by T cells,” Glycobiology, vol. 7, no. 6, pp. 725–730, 1997. View at Scopus
  69. C. A. Janeway Jr., B. E. Cohen, S. Z. Ben Sasson, and W. E. Paul, “The specificity of cellular immune responses in guinea pigs. I. T cells specific for 2,4 dinitrophenyl O tyrosyl residues,” Journal of Experimental Medicine, vol. 141, no. 1, pp. 42–55, 1975. View at Scopus
  70. U. M. Abdel-Motal, L. Berg, and L. Berg, “Immunization with glycosylated Kb-binding peptides generates carbohydrate-specific, unrestricted cytotoxic T cells,” European Journal of Immunology, vol. 26, no. 3, pp. 544–551, 1996. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  71. E. Michaëlsson, J. Broddefalk, Å. Engström, J. Kihlberg, and R. Holmdahl, “Antigen processing and presentation of a naturally glycosylated protein elicits major histocompatibility complex class II-restricted, carbohydrate-specific T cells,” European Journal of Immunology, vol. 26, no. 8, pp. 1906–1910, 1996. View at Scopus
  72. A. Franco, “CTL-based cancer preventive/therapeutic vaccines for carcinomas: role of tumour-associated carbohydrate antigens,” Scandinavian Journal of Immunology, vol. 61, no. 5, pp. 391–397, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  73. L. Galli-Stampino, E. Meinjohanns, K. Frische, M. Meldal, T. Jensen, O. Werdelin, and S. Mouritsen, “T-cell recognition of tumor-associated carbohydrates: the nature of the glycan moiety plays a decisive role in determining glycopeptide immunogenicity,” Cancer Research, vol. 57, no. 15, pp. 3214–3222, 1997. View at Scopus
  74. A. Glithero, J. Tormo, and J. Tormo, “Crystal structures of two H-2Db/glycopeptide complexes suggest a molecular basis for CTL cross-reactivity,” Immunity, vol. 10, no. 1, pp. 63–74, 1999. View at Publisher · View at Google Scholar · View at Scopus
  75. J. S. Haurum, G. Arsequell, A. C. Lellouch, S. Y. C. Wong, R. A. Dwek, A. J. McMichael, and T. Elliott, “Recognition of carbohydrate by major histocompatibility complex class I-restricted, glycopeptide-specific cytotoxic T lymphocytes,” Journal of Experimental Medicine, vol. 180, no. 2, pp. 739–744, 1994. View at Publisher · View at Google Scholar · View at Scopus
  76. J. S. Haurum, L. Tan, and L. Tan, “Peptide anchor residue glycosylation: effect on class I major histocompatibility complex binding and cytotoxic T lymphocyte recognition,” European Journal of Immunology, vol. 25, no. 12, pp. 3270–3276, 1995. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  77. T. Jensen, L. Galli-Stampino, S. Mouritsen, K. Frische, S. Peters, M. Meldal, and O. Werdelin, “T cell recognition of Tn-glycosylated peptide antigens,” European Journal of Immunology, vol. 26, no. 6, pp. 1342–1349, 1996. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  78. T. Jensen, P. Hansen, and P. Hansen, “Carbohydrate and peptide specificity of MHC class II-restricted T cell hybridomas raised against an O-glycosylated self peptide,” Journal of Immunology, vol. 158, no. 8, pp. 3769–3778, 1997. View at Scopus
  79. I. B. Kastrup, S. Stevanovic, and S. Stevanovic, “Lectin purified human class I MHC-derived peptides: evidence for presentation of glycopeptides in vivo,” Tissue Antigens, vol. 56, no. 2, pp. 129–135, 2000. View at Publisher · View at Google Scholar · View at Scopus
  80. J. A. Speir, U. M. Abdel-Motal, M. Jondal, and I. A. Wilson, “Crystal structure of an MHC class I presented glycopeptide that generates carbohydrate-specific CTL,” Immunity, vol. 10, no. 1, pp. 51–61, 1999. View at Publisher · View at Google Scholar · View at Scopus
  81. D. Stepensky, E. Tzehoval, E. Vadai, and L. Eisenbach, “O-glycosylated versus non-glycosylated MUC1-derived peptides as potential targets for cytotoxic immunotherapy of carcinoma,” Clinical and Experimental Immunology, vol. 143, no. 1, pp. 139–149, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  82. Y. Xu, S. J. Gendler, and A. Franco, “Designer glycopeptides for cytotoxic T cell-based elimination of carcinomas,” Journal of Experimental Medicine, vol. 199, no. 5, pp. 707–716, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  83. B. M. Sandmaier, D. V. Oparin, L. A. Holmberg, M. A. Reddish, G. D. MacLean, and B. M. Longenecker, “Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, and immunization with Theratope STn-KLH cancer vaccine,” Journal of Immunotherapy, vol. 22, no. 1, pp. 54–66, 1999. View at Publisher · View at Google Scholar · View at Scopus
  84. C. M. Böhm, M. C. Mulder, and M. C. Mulder, “Carbohydrate recognition on MUC1-expressing targets enhances cytotoxicity of a T cell subpopulation,” Scandinavian Journal of Immunology, vol. 46, no. 1, pp. 27–34, 1997. View at Scopus
  85. A. Franco, “Glycoconjugates as vaccines for cancer immunotherapy: clinical trials and future directions,” Anti-Cancer Agents in Medicinal Chemistry, vol. 8, no. 1, pp. 86–91, 2008. View at Publisher · View at Google Scholar · View at Scopus
  86. V. Apostolopoulos, C. Osinski, and I. F. C. McKenzie, “MUC1 cross-reactive Galα(1,3)Gal antibodies in humans switch immune responses from cellular to humoral,” Nature Medicine, vol. 4, no. 3, pp. 315–320, 1998. View at Publisher · View at Google Scholar · View at Scopus
  87. V. Apostolopoulos, M. S. Sandrin, and I. F. C. McKenzie, “Mimics and cross reactions of relevance to tumour immunotherapy,” Vaccine, vol. 18, no. 3-4, pp. 268–275, 1999. View at Publisher · View at Google Scholar · View at Scopus
  88. G. D. MacLean, M. A. Reddish, R. R. Koganty, and B. M. Longenecker, “Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine,” Journal of Immunotherapy, vol. 19, no. 1, pp. 59–68, 1996. View at Scopus
  89. M. S. Sandrin, H. A. Vaughan, P.-X. Xing, and I. F. C. McKenzie, “Natural human anti-Galα(1,3)Gal antibodies react with human mucin peptides,” Glycoconjugate Journal, vol. 14, no. 1, pp. 97–105, 1997. View at Publisher · View at Google Scholar · View at Scopus
  90. B. Monzavi-Karbassi, G. Cunto-Amesty, P. Luo, A. Lees, and T. Kieber-Emmons, “Immunological characterization of peptide mimetics of carbohydrate antigens in vaccine design strategies,” Biologicals, vol. 29, no. 3-4, pp. 249–257, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  91. B. Monzavi-Karbassi, P. Luo, F. Jousheghany, M. Torres-Quiñones, G. Cunto-Amesty, C. Artaud, and T. Kieber-Emmons, “A mimic of tumor rejection antigen-associated carbohydrates mediates an antitumor cellular response,” Cancer Research, vol. 64, no. 6, pp. 2162–2166, 2004. View at Publisher · View at Google Scholar · View at Scopus
  92. B. Monzavi-Karbassi, S. Shamloo, and S. Shamloo, “Priming characteristics of peptide mimotopes of carbohydrate antigens,” Vaccine, vol. 21, no. 7-8, pp. 753–760, 2003. View at Publisher · View at Google Scholar · View at Scopus
  93. G. Cunto-Amesty, P. Luo, B. Monzavi-Karbassi, A. Lees, and T. Kieber-Emmons, “Exploiting molecular mimicry to broaden the immune response to carbohydrate antigens for vaccine development,” Vaccine, vol. 19, no. 17–19, pp. 2361–2368, 2001. View at Publisher · View at Google Scholar · View at Scopus
  94. T. Kottke, J. Pulido, and J. Pulido, “Antitumor immunity can be uncoupled from autoimmunity following heat shock protein 70-mediated inflammatory killing of normal pancreas,” Cancer Research, vol. 69, no. 19, pp. 7767–7774, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  95. K. L. Knutson and M. L. Disis, “Tumor antigen-specific T helper cells in cancer immunity and immunotherapy,” Cancer Immunology, Immunotherapy, vol. 54, no. 8, pp. 721–728, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  96. K. Hung, R. Hayashi, A. Lafond-Walker, C. Lowenstein, D. Pardoll, and H. Levitsky, “The central role of CD4+ T cells in the antitumor immune response,” Journal of Experimental Medicine, vol. 188, no. 12, pp. 2357–2368, 1998. View at Publisher · View at Google Scholar · View at Scopus
  97. R.-F. Wang, “The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity,” Trends in Immunology, vol. 22, no. 5, pp. 269–276, 2001. View at Publisher · View at Google Scholar · View at Scopus
  98. A. M. Livingstone, E. B. Wilson, F. Ontiveros, and J.-C.E. Wang, “Unravelling the mechanisms of help for CD8+ T cell responses,” Immunologic Research, vol. 45, no. 2-3, pp. 209–217, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  99. C. A. Black, “Delayed type hypersensitivity: current theories with an historic perspective,” Dermatology Online Journal, vol. 5, no. 1, p. 7, 1999. View at Scopus
  100. M. Osorio, E. Gracia, and E. Gracia, “Heterophilic NeuGcGM3 ganglioside cancer vaccine in advanced melanoma patients: results of a Phase Ib/IIa study,” Cancer Biology and Therapy, vol. 7, no. 4, pp. 488–495, 2008. View at Scopus
  101. S. K. Kim, G. Ragupathi, S. Cappello, E. Kagan, and P. O. Livingston, “Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-KLH and GD3-KLH conjugates,” Vaccine, vol. 19, no. 4-5, pp. 530–537, 2000. View at Publisher · View at Google Scholar · View at Scopus
  102. M. H. Ravindranath, P. M. Bauer, A. A. Amiri, S. M. Miri, M. C. Kelley, R. C. Jones, and D. L. Morton, “Cellular cancer vaccine induces delayed-type hypersensitivity reaction and augments antibody response to tumor-associated carbohydrate antigens (sialyl Lea, sialyl Lex, GD3 and GM2) better than soluble lysate cancer vaccine,” Anti-Cancer Drugs, vol. 8, no. 3, pp. 217–224, 1997. View at Publisher · View at Google Scholar · View at Scopus
  103. P. Puccetti, R. Bianchi, L. Romani, E. Cenci, and M. C. Fioretti, “Delayed-type hypersensitivity to tumor antigens co-expressed with immunogenic determinants induced by xenogenization,” International Journal of Cancer, vol. 43, no. 2, pp. 279–284, 1989. View at Scopus
  104. E. Kuramoto, N. Watanabe, D. Iwata, O. Yano, S. Shimada, and T. Tokunaga, “Changes of host cell infiltration into Meth A fibrosarcoma tumor during the course of regression induced by injections of a BCG nucleic acid fraction,” International Journal of Immunopharmacology, vol. 14, no. 5, pp. 773–782, 1992. View at Publisher · View at Google Scholar · View at Scopus
  105. M. Szczepanik, M. Akahira-Azuma, and M. Akahira-Azuma, “B-1 B cells mediate required early T cell recruitment to elicit protein-induced delayed-type hypersensitivity,” Journal of Immunology, vol. 171, no. 11, pp. 6225–6235, 2003. View at Scopus
  106. R. F. Tsuji, M. Szczepanik, and M. Szczepanik, “B cell-dependent T cell responses: IgM antibodies are required to elicit contact sensitivity,” Journal of Experimental Medicine, vol. 196, no. 10, pp. 1277–1290, 2002. View at Publisher · View at Google Scholar · View at Scopus
  107. H. Schreiber, T. H. Wu, J. Nachman, and D. A. Rowley, “Immunological enhancement of primary tumor development and its prevention,” Seminars in Cancer Biology, vol. 10, no. 5, pp. 351–357, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  108. H. P. Vollmers and S. Brändlein, “The “early birds”: natural IgM antibodies and immune surveillance,” Histology and Histopathology, vol. 20, no. 3, pp. 927–937, 2005. View at Scopus
  109. G. Dighiero, P. Lymberi, D. Holmberg, et al., “High frequency of natural autoantibodies in normal newborn mice,” Journal of Immunology, vol. 134, no. 2, pp. 765–771, 1985. View at Scopus
  110. J. Gil, R. Alvarez, J. E. Vinuela, J. G. Ruiz De Morales, A. Bustos, E. G. De La Concha, and J. L. Subiza, “Inhibition of in vivo tumor growth by a monoclonal IgM antibody recognizing tumor cell surface carbohydrates,” Cancer Research, vol. 50, no. 22, pp. 7301–7306, 1990. View at Scopus
  111. X. Zhong, W. Gao, and W. Gao, “Reciprocal generation of Th1/Th17 and Treg cells by B1 and B2 B cells,” European Journal of Immunology, vol. 37, no. 9, pp. 2400–2404, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  112. M. Croft and S. L. Swain, “Analysis of CD4+ T cells that provide contact-dependent bystander help to B cells,” Journal of Immunology, vol. 149, no. 10, pp. 3157–3165, 1992. View at Scopus
  113. B. Monzavi-Karbassi, L. J. Hennings, and L. J. Hennings, “Preclinical studies of carbohydrate mimetic peptide vaccines for breast cancer and melanoma,” Vaccine, vol. 25, no. 16, pp. 3022–3031, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  114. A. Wondimu, T. Zhang, and T. Zhang, “Peptides mimicking GD2 ganglioside elicit cellular, humoral and tumor-protective immune responses in mice,” Cancer Immunology, Immunotherapy, vol. 57, no. 7, pp. 1079–1089, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  115. Y. D. Dai, G. Carayanniotis, and E. Sercarz, “Antigen processing by autoreactive B cells promotes determinant spreading,” Cellular & Molecular Immunology, vol. 2, no. 3, pp. 169–175, 2005. View at Scopus
  116. S. Deola, M. C. Panelli, and M. C. Panelli, “Helper B cells promote cytotoxic T cell survival and proliferation independently of antigen presentation through CD27/CD70 interactions,” Journal of Immunology, vol. 180, no. 3, pp. 1362–1372, 2008. View at Scopus
  117. P. W. Askenase, “Yes T cells, but three different T cells (αβ, γσ and NK T cells), and also B-1 cells mediate contact sensitivity,” Clinical and Experimental Immunology, vol. 125, no. 3, pp. 345–350, 2001. View at Publisher · View at Google Scholar · View at Scopus
  118. T. Matsushita, K. Yanaba, J.-D. Bouaziz, M. Fujimoto, and T. F. Tedder, “Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression,” Journal of Clinical Investigation, vol. 118, no. 10, pp. 3420–3430, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  119. T. Matsushita, “Immunological memory,” Advances in Immunology, vol. 53, pp. 217–265, 2008.
  120. A. F. Ochsenbein and R. M. Zinkernagel, “Natural antibodies and complement link innate and acquired immunity,” Immunology Today, vol. 21, no. 12, pp. 624–630, 2000. View at Publisher · View at Google Scholar · View at Scopus
  121. M. E. Youd, A. R. Ferguson, and R. B. Corley, “Synergistic roles of IgM and complement in antigen trapping and follicular localization,” European Journal of Immunology, vol. 32, no. 8, pp. 2328–2337, 2002. View at Publisher · View at Google Scholar · View at Scopus
  122. H. Von Boehmer, I. Aifantis, and I. Aifantis, “Thymic selection revisited: how essential is it?” Immunological Reviews, vol. 191, pp. 62–78, 2003. View at Publisher · View at Google Scholar · View at Scopus
  123. M.-L. Lin, Y. Zhan, J. A. Villadangos, and A. M. Lew, “The cell biology of cross-presentation and the role of dendritic cell subsets,” Immunology and Cell Biology, vol. 86, no. 4, pp. 353–362, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  124. M. J. Bevan, “Cross priming for a secondary cytotoxic respsonse to minor H antigens with H-2 congenic cells which do not cross react in the cytotoxic assay,” Journal of Experimental Medicine, vol. 143, no. 5, pp. 1283–1288, 1976. View at Scopus
  125. A. Heit, F. Schmitz, M. O'Keeffe, C. Staib, D. H. Busch, H. Wagner, and K. M. Huster, “Protective CD8 T cell immunity triggered by CpG-protein conjugates competes with the efficacy of live vaccines,” Journal of Immunology, vol. 174, no. 7, pp. 4373–4380, 2005. View at Scopus
  126. J. B. Ulmer, R. R. Deck, C. M. Dewitt, J. J. Donnelly, and M. A. Liu, “Generation of MHC class I-restricted cytotoxic T lymphocytes by expression of a viral protein in muscle cells: antigen presentation by non-muscle cells,” Immunology, vol. 89, no. 1, pp. 59–67, 1996. View at Scopus
  127. J. S. Boyle, C. Koniaras, and A. M. Lew, “Influence of cellular location of expressed antigen on the efficacy of DNA vaccination: cytotoxic T lymphocyte and antibody responses are suboptimal when antigen is cytoplasmic after intramuscular DNA immunization,” International Immunology, vol. 9, no. 12, pp. 1897–1906, 1997. View at Publisher · View at Google Scholar · View at Scopus
  128. A. Murshid, J. Gong, and S. K. Calderwood, “Heat-shock proteins in cancer vaccines: agents of antigen cross-presentation,” Expert Review of Vaccines, vol. 7, no. 7, pp. 1019–1030, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  129. K. Shimizu, Y. Kurosawa, M. Taniguchi, R. M. Steinman, and S.-I. Fujii, “Cross-presentation of glycolipid from tumor cells loaded with α-galactosylceramide leads to potent and long-lived T cell-mediated immunity via dendritic cells,” Journal of Experimental Medicine, vol. 204, no. 11, pp. 2641–2653, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  130. D. Valmori, N. E. Souleimanian, and N. E. Souleimanian, “Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 21, pp. 8947–8952, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  131. C. H. Qiu, Y. Miyake, H. Kaise, H. Kitamura, O. Ohara, and M. Tanaka, “Novel subset of CD8α+ dendritic cells localized in the marginal zone is responsible for tolerance to cell-associated antigens,” Journal of Immunology, vol. 182, no. 7, pp. 4127–4136, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  132. S. O. Harbers, A. Crocker, G. Catalano, V. D'Agati, S. Jung, D. D. Desai, and R. Clynes, “Antibody-enhanced cross-presentation of self antigen breaks T cell tolerance,” Journal of Clinical Investigation, vol. 117, no. 5, pp. 1361–1369, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  133. T. A. Ferguson, J. Herndon, B. Elzey, T. S. Griffith, S. Schoenberger, and D. R. Green, “Uptake of apoptotic antigen-coupled cells by lymphoid dendritic cells and cross-priming of CD8+ T cells produce active immune unresponsiveness,” Journal of Immunology, vol. 168, no. 11, pp. 5589–5595, 2002. View at Scopus
  134. S. Freigang, D. Egger, K. Bienz, H. Hengartner, and R. M. Zinkernagel, “Endogenous neosynthesis vs. cross-presentation of viral antigens for cytotoxic T cell priming,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 23, pp. 13477–13482, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  135. R. M. Zinkernagel, “On cross-priming of MHC class I-specific CTL: rule or exception?” European Journal of Immunology, vol. 32, no. 9, pp. 2385–2392, 2002. View at Publisher · View at Google Scholar · View at Scopus
  136. A. Knuth, B. Danowski, H. F. Oettgen, and L. J. Old, “T-cell-mediated cytotoxicity against autologous malignant melanoma: analysis with interleukin 2-dependent T-cell cultures,” Proceedings of the National Academy of Sciences of the United States of America, vol. 81, no. 11, pp. 3511–3515, 1984. View at Scopus
  137. T. M. Kundig, M. F. Bachmann, L. Lefrancois, L. Puddington, H. Hengartner, and R. M. Zinkernagel, “Nonimmunogenic tumor cells may efficiently restimulate tumor antigen-specific cytotoxic T cells,” Journal of Immunology, vol. 150, no. 10, pp. 4450–4456, 1993. View at Scopus
  138. D. J. Schendel, B. Gansbacher, R. Oberneder, M. Kriegmair, A. Hofstetter, G. Riethmuller, and O. G. Segurado, “Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes: I. HLA-A2-restricted recognition of autologous and allogeneic tumor lines,” Journal of Immunology, vol. 151, no. 8, pp. 4209–4220, 1993. View at Scopus
  139. M. Schnurr, P. Galambos, C. Scholz, F. Then, M. Dauer, S. Endres, and A. Eigler, “Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines,” Cancer Research, vol. 61, no. 17, pp. 6445–6450, 2001. View at Scopus
  140. P. A. Würtzen, L. Ø. Pedersen, H. S. Poulsen, and M. H. Claesson, “Specific killing of p53 mutated tumor cell lines by a cross-reactive human HLA-A2-restricted p53-specific CTL line,” International Journal of Cancer, vol. 93, no. 6, pp. 855–861, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  141. K. M. Zirlik, D. Zahrieh, D. Neuberg, and J. G. Gribben, “Cytotoxic T cells generated against heteroclitic peptides kill primary tumor cells independent of the binding affinity of the native tumor antigen peptide,” Blood, vol. 108, no. 12, pp. 3865–3870, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  142. B. Wang, J. M. Y. Kuroiwa, L.-Z. He, A. Charalambous, T. Keler, and R. M. Steinman, “The human cancer antigen mesothelin is more efficiently presented to the mouse immune system when targeted to the DEC-205/CD205 receptor on dendritic cells,” Annals of the New York Academy of Sciences, vol. 1174, pp. 6–17, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  143. U. Galili, “Autologous tumor vaccines processed to express α-gal epitopes: a practical approach to immunotherapy in cancer,” Cancer Immunology, Immunotherapy, vol. 53, no. 11, pp. 935–945, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  144. I. F. Hermans, D. S. Ritchie, J. Yang, J. M. Roberts, and F. Ronchese, “CD8+ T cell-dependent elimination of dendritic cells in vivo limits the induction of antitumor immunity,” Journal of Immunology, vol. 164, no. 6, pp. 3095–3101, 2000. View at Scopus
  145. D. C. Kilpatrick, “Animal lectins: a historical introduction and overview,” Biochimica et Biophysica Acta, vol. 1572, no. 2-3, pp. 187–197, 2002. View at Publisher · View at Google Scholar · View at Scopus
  146. L. East and C. M. Isacke, “The mannose receptor family,” Biochimica et Biophysica Acta, vol. 1572, no. 2-3, pp. 364–386, 2002. View at Publisher · View at Google Scholar · View at Scopus
  147. R. E. Shrimpton, M. Butler, A.-S. Morel, E. Eren, S. S. Hue, and M. A. Ritter, “CD205 (DEC-205): a recognition receptor for apoptotic and necrotic self,” Molecular Immunology, vol. 46, no. 6, pp. 1229–1239, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  148. S. Burgdorf, V. Lukacs-Kornek, and C. Kurts, “The mannose receptor mediates uptake of soluble but not of cell-associated antigen for cross-presentation,” Journal of Immunology, vol. 176, no. 11, pp. 6770–6776, 2006. View at Scopus
  149. V. Ramakrishna, J. F. Treml, and J. F. Treml, “Mannose receptor targeting of tumor antigen pmel17 to human dendritic cells directs anti-melanoma T cell responses via multiple HLA molecules,” Journal of Immunology, vol. 172, no. 5, pp. 2845–2852, 2004. View at Scopus
  150. L.-Z. He, A. Crocker, and A. Crocker, “Antigenic targeting of the human mannose receptor induces tumor immunity,” Journal of Immunology, vol. 178, no. 10, pp. 6259–6267, 2007. View at Scopus
  151. S. Dasgupta, A.-M. Navarrete, and A.-M. Navarrete, “A role for exposed mannosylations in presentation of human therapeutic self-proteins to CD4+ T lymphocytes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 21, pp. 8965–8970, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  152. M. Chieppa, G. Bianchi, and G. Bianchi, “Cross-linking of the mannose receptor on monocyte-derived dendritic cells activates an anti-inflammatory immunosuppressive program,” Journal of Immunology, vol. 171, no. 9, pp. 4552–4560, 2003. View at Scopus
  153. J. Idoyaga, C. Cheong, and C. Cheong, “Cutting edge: langerin/CD207 receptor on dendritic cells mediates efficient antigen presentation on MHC I and II products in vivo,” Journal of Immunology, vol. 180, no. 6, pp. 3647–3650, 2008. View at Scopus
  154. S. K. Singh, J. Stephani, and J. Stephani, “Targeting glycan modified OVA to murine DC-SIGN transgenic dendritic cells enhances MHC class I and II presentation,” Molecular Immunology, vol. 47, no. 2-3, pp. 164–174, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  155. K. Takahara, Y. Omatsu, and Y. Omatsu, “Identification and expression of mouse Langerin (CD207) in dendritic cells,” International Immunology, vol. 14, no. 5, pp. 433–444, 2002. View at Scopus
  156. I. van Die, S. J. van Vliet, and S. J. van Vliet, “The dendritic cell-specific C-type lectin DC-SIGN is a receptor for Schistosoma mansoni egg antigens and recognizes the glycan antigen Lewis x,” Glycobiology, vol. 13, no. 6, pp. 471–478, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  157. C. Galustian, C. G. Park, and C. G. Park, “High and low affinity carbohydrate ligands revealed for murine SIGN-R1 by carbohydrate array and cell binding approaches, and differing specificities for SIGN-R3 and langerin,” International Immunology, vol. 16, no. 6, pp. 853–866, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  158. B. Monzavi-Karbassi, P. Luo, G. Cunto-Amesty, F. Jousheghany, A. Pashov, D. Weissman, and T. Kieber-Emmons, “Fucosylated lactosamines participate in adhesion of HIV-1 envelope glycoprotein to dendritic cells,” Archives of Virology, vol. 149, no. 1, pp. 75–91, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  159. M. Ujita, H. Nagayama, S. Kanie, S. Koike, Y. Ikeyama, T. Ozaki, and H. Okumura, “Carbohydrate binding specificity of recombinant human macrophage β-glucan receptor dectin-1,” Bioscience, Biotechnology and Biochemistry, vol. 73, no. 1, pp. 237–240, 2009. View at Publisher · View at Google Scholar · View at Scopus
  160. G. Ferwerda, F. Meyer-Wentrup, B.-J. Kullberg, M. G. Netea, and G. J. Adema, “Dectin-1 synergizes with TLR2 and TLR4 for cytokine production in human primary monocytes and macrophages,” Cellular Microbiology, vol. 10, no. 10, pp. 2058–2066, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  161. S. Dillon, S. Agrawal, and S. Agrawal, “Yeast zymosan, a stimulus for TLR2 and dectin-1, induces regulatory antigen-presenting cells and immunological tolerance,” Journal of Clinical Investigation, vol. 116, no. 4, pp. 916–928, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  162. P. Hernanz-Falcón, O. Joffre, D. L. Williams, and C. Reis e Sousa, “Internalization of dectin-1 terminates induction of inflammatory responses,” European Journal of Immunology, vol. 39, no. 2, pp. 507–513, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  163. M. M. Weck, S. Appel, D. Werth, C. Sinzger, A. Bringmann, F. Grünebach, and P. Brossart, “HDectin-1 is involved in uptake and cross-presentation of cellular antigens,” Blood, vol. 111, no. 8, pp. 4264–4272, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  164. D. Sancho, D. Mourão-Sá, and D. Mourão-Sá, “Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin,” Journal of Clinical Investigation, vol. 118, no. 6, pp. 2098–2110, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  165. D. Sancho, O. P. Joffre, and O. P. Joffre, “Identification of a dendritic cell receptor that couples sensing of necrosis to immunity,” Nature, vol. 458, no. 7240, pp. 899–903, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  166. K. Mahnke, Y. Qian, J. Knop, and A. H. Enk, “Induction of CD4+/CD25+ regulatory T cells by targeting of antigens to immature dendritic cells,” Blood, vol. 101, no. 12, pp. 4862–4869, 2003. View at Scopus
  167. M. Cohn, “A rationalized set of default postulates that permit a coherent description of the immune system amenable to computer modeling,” Scandinavian Journal of Immunology, vol. 68, no. 4, pp. 371–380, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  168. T. Moore, C. O. Ekworomadu, and C. O. Ekworomadu, “Fc receptor-mediated antibody regulation of T cell immunity against intracellular pathogens,” Journal of Infectious Diseases, vol. 188, no. 4, pp. 617–624, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  169. A. Casadevall and L. Pirofski, “Insights into mechanisms of antibody-mediated immunity from studies with Cryptococcus neoformans,” Current Molecular Medicine, vol. 5, no. 4, pp. 421–433, 2005. View at Publisher · View at Google Scholar · View at Scopus
  170. J. M. M. den Haan and M. J. Bevan, “Constitutive versus activation-dependent cross-presentation of immune complexes by CD8+ and CD8- dendritic cells in vivo,” Journal of Experimental Medicine, vol. 196, no. 6, pp. 817–827, 2002. View at Publisher · View at Google Scholar · View at Scopus
  171. K. M. Dhodapkar, J. Krasovsky, B. Williamson, and M. V. Dhodapkar, “Antitumor monoclonal antibodies enhance cross-presentation of cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells,” Journal of Experimental Medicine, vol. 195, no. 1, pp. 125–133, 2002. View at Publisher · View at Google Scholar · View at Scopus
  172. A. Dürrbach, E. Baple, A. F. Preece, B. Charpentier, and K. Gustafsson, “Virus recognition by specific natural antibodies and complement results in MHC I cross-presentation,” European Journal of Immunology, vol. 37, no. 5, pp. 1254–1265, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  173. N. van Montfoort, J. M. H. de Jong, and J. M. H. de Jong, “A novel role of complement factor C1q in augmenting the presentation of antigen captured in immune complexes to CD8+ T lymphocytes,” Journal of Immunology, vol. 178, no. 12, pp. 7581–7586, 2007. View at Scopus
  174. K. Rafiq, A. Bergtold, and R. Clynes, “Immune complex-mediated antigen presentation induces tumor immunity,” Journal of Clinical Investigation, vol. 110, no. 1, pp. 71–79, 2002. View at Publisher · View at Google Scholar · View at Scopus
  175. Y. Liu, X. Gao, E. Masuda, P. B. Redecha, M. C. Blank, and L. Pricop, “Regulated expression of FcγR in human dendritic cells controls cross-presentation of antigen-antibody complexes,” Journal of Immunology, vol. 177, no. 12, pp. 8440–8447, 2006. View at Scopus
  176. F. Nimmerjahn and J. V. Ravetch, “Antibodies, Fc receptors and cancer,” Current Opinion in Immunology, vol. 19, no. 2, pp. 239–245, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  177. F. Nimmerjahn and J. V. Ravetch, “Immunology: divergent immunoglobulin G subclass activity through selective Fc receptor binding,” Science, vol. 310, no. 5753, pp. 1510–1512, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  178. A. Wierzbicki, M. Gil, and M. Gil, “Immunization with a mimotope of GD2 ganglioside induces CD8+ T cells that recognize cell adhesion molecules on tumor cells,” Journal of Immunology, vol. 181, no. 9, pp. 6644–6653, 2008. View at Scopus
  179. C. Ding, L. Wang, J. Marroquin, and J. Yan, “Targeting of antigens to B cells augments antigen-specific T-cell responses and breaks immune tolerance to tumor-associated antigen MUC1,” Blood, vol. 112, no. 7, pp. 2817–2825, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  180. K. R. Jerome, N. Domenech, and O. J. Finn, “Tumor-specific cytotoxic T cell clones from patients with breast and pancreatic adenocarcinoma recognize EBV-immortalized B cells transfected with polymorphic epithelial mucin complementary DNA,” Journal of Immunology, vol. 151, no. 3, pp. 1654–1662, 1993. View at Scopus
  181. J. Taylor-Papadimitriou and O. J. Finn, “Biology, biochemistry and immunology of carcinoma-associated mucins,” Immunology Today, vol. 18, no. 3, pp. 105–107, 1997. View at Publisher · View at Google Scholar · View at Scopus
  182. G. Denton, M. Sekowski, and M. R. Price, “Induction of antibody responses to breast carcinoma associated mucins using synthetic peptide constructs as immunogens,” Cancer Letters, vol. 70, no. 3, pp. 143–150, 1993. View at Publisher · View at Google Scholar · View at Scopus
  183. L.-G. Yu, J. D. Milton, D. G. Fernig, and J. M. Rhodes, “Opposite effects on human colon cancer cell proliferation of two dietary Thomse-Friedenreich antigen-binding lectins,” Journal of Cellular Physiology, vol. 186, no. 2, pp. 282–287, 2001. View at Publisher · View at Google Scholar · View at Scopus
  184. F. J. Irazoqui, B. Jansson, P. H. H. Lopez, and G. A. Nores, “Correlative fine specificity of several Thomsen-Friedenreich disaccharide-binding proteins with an effect on tumor cell proliferation,” Journal of Biochemistry, vol. 130, no. 1, pp. 33–37, 2001. View at Scopus
  185. V. Apostolopoulos, V. Karanikas, J. S. Haurum, and I. F. C. McKenzie, “Induction of HLA-A2-restricted CTLs to the mucin 1 human breast cancer antigen,” Journal of Immunology, vol. 159, no. 11, pp. 5211–5218, 1997. View at Scopus
  186. B. J. Hebeis, K. Klenovsek, P. Rohwer, U. Ritter, A. Schneider, M. Mach, and T. H. Winkler, “Activation of virus-specific memory B cells in the absence of T cell help,” Journal of Experimental Medicine, vol. 199, no. 4, pp. 593–602, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  187. B. Peters, J. Sidney, and J. Sidney, “The immune epitope database and analysis resource: from vision to blueprint,” PLoS Biology, vol. 3, no. 3, article e91, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  188. M. Moutaftsi, B. Peters, and B. Peters, “A consensus epitope prediction approach identifies the breadth of murine TCD8+-cell responses to vaccinia virus,” Nature Biotechnology, vol. 24, no. 7, pp. 817–819, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  189. C. Lundegaard, K. Lamberth, M. Harndahl, S. Buus, O. Lund, and M. Nielsen, “NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11,” Nucleic Acids Research, vol. 36, web server issue, pp. W509–W512, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  190. A. S. De Groot, J. McMurry, and L. Moise, “Prediction of immunogenicity: in silico paradigms, ex vivo and in vivo correlates,” Current Opinion in Pharmacology, vol. 8, no. 5, pp. 620–626, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  191. A. S. De Groot, L. Moise, and L. Moise, “Activation of natural regulatory T cells by IgG Fc-derived peptide “Tregitopes”,” Blood, vol. 112, no. 8, pp. 3303–3311, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  192. F. Rahbarizadeh, M. J. Rasaee, M. Forouzandeh, A. Allameh, R. Sarrami, H. Nasiry, and M. Sadeghizadeh, “The production and characterization of novel heavy-chain antibodies against the tandem repeat region of MUC1 mucin,” Immunological Investigations, vol. 34, no. 4, pp. 431–452, 2005. View at Publisher · View at Google Scholar · View at Scopus
  193. M. V. Croce, M. T. Isla-Larrain, A. Capafons, M. R. Price, and A. Segal-Eiras, “Humoral immune response induced by the protein core of MUC1 mucin in pregnant and healthy women,” Breast Cancer Research and Treatment, vol. 69, no. 1, pp. 1–11, 2001. View at Publisher · View at Google Scholar · View at Scopus